Springer celebrates 175 years of publishing excellence! Join us >>

Milestones in Drug Therapy

Drugs for HER-2-positive Breast Cancer

Editors: Sibilia, M., Zielinski, C.C., Bergen, E., Grunt, Th.W. (Eds.)

  • Contemporary monograph on the treatment of breast cancer.-
  • Gives a comprehensive account of drugs for HER2-positive breast cancer.-
  • A valuable source of information for researchers and clinicians from the fields of oncology and pharmacology
see more benefits

Buy this book

eBook $149.00
price for USA (gross)
  • ISBN 978-3-0346-0094-1
  • Digitally watermarked, DRM-free
  • Included format: EPUB, PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $189.00
price for USA
  • ISBN 978-3-0346-0093-4
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Softcover $189.00
price for USA
  • ISBN 978-3-0348-0318-2
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
About this book

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

Reviews

From the reviews:

“This book takes readers on a journey from HER-2 signalling to therapeutic use of trastuzumab in the neoadjuvant, adjuvant and metastatic settings. … It is a tour-de-force and should be essential reading for anyone setting out in the HER-2 research field. … Overall, this small book covers the topic of HER-2 inhibition very well in a field that is rapidly changing.” (S. W. Wong and R. M. Lowenthal, Inflammation Research, Vol. 61, 2012)


Table of contents (6 chapters)

  • The EGFR/ErbB Family in Breast Cancer: From Signalling to Therapy

    Köstler, Wolfgang J. (et al.)

    Pages 1-32

  • Trastuzumab as Adjuvant Treatment for Early Stage HER-2-positive Breast Cancer

    Bartsch, Rupert (et al.)

    Pages 33-49

  • Trastuzumab Resistance in Breast Cancer

    Morgillo, Floriana (et al.)

    Pages 51-60

  • Treatment with Trastuzumab Beyond Progression

    Minckwitz, Gunter (et al.)

    Pages 61-71

  • Pertuzumab – a HER-2 Dimerisation Inhibitor – for the Treatment of Breast and Other Cancers

    Bianchi, Giulia (et al.)

    Pages 73-90

Buy this book

eBook $149.00
price for USA (gross)
  • ISBN 978-3-0346-0094-1
  • Digitally watermarked, DRM-free
  • Included format: EPUB, PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $189.00
price for USA
  • ISBN 978-3-0346-0093-4
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Softcover $189.00
price for USA
  • ISBN 978-3-0348-0318-2
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
Drugs for HER-2-positive Breast Cancer
Editors
  • Maria Sibilia
  • Christoph C. Zielinski
  • Elisabeth Bergen
  • Thomas W. Grunt
Series Title
Milestones in Drug Therapy
Copyright
2011
Publisher
Springer Basel
Copyright Holder
Springer Basel AG
eBook ISBN
978-3-0346-0094-1
DOI
10.1007/978-3-0346-0094-1
Hardcover ISBN
978-3-0346-0093-4
Softcover ISBN
978-3-0348-0318-2
Series ISSN
2296-6056
Edition Number
1
Number of Pages
X, 110
Topics